About this trial

The goal of the current research is to develop personalized risk prediction for functional mitral regurgitation (FMR) patients through explainable unsupervised phenomapping enriched with advanced cardiac magnetic resonance (CMR) imaging biomarkers, and to determine the CMR predictors of reverse remodeling following modern therapies for FMR.

The prospective study entails aiming to recruit 360 adult patients (ages \>18 years) with EF 10-50% and FMR RF\> 20%, who are clinically referred for CMR evaluation. Patients who enroll in our study will be referred for optimization of mGDMT and will undergo follow-up CMR studies at 6months. NICM patients who are fully medically optimized with significant FMR at the time of the baseline CMR and are referred for Mitraclip treatment will undergo follow-up CMR 6 months from Mitraclip intervention. NICM patients referred for mGDMT optimization, but have persistent or progressive FMR at the time of 6 month follow-up CMR and referred for Mitraclip therapy, will undergo a 2nd follow-up CMR 6 months from Mitraclip therapy.

Eligibility criteria

Qualifiers

None

Disqualifiers

>moderate aortic regurgitation/stenosis,

<18 years of age,

acute myocarditis,

eGFR<15

Trial design

Treatments tested in this trial

  • Cardiac magnetic resonance (CMR)

Treatment groups

360 Participants
are divided into 2 treatment groups

Locations

1
Cleveland Clinic44195, ClevelandOhio, United States

Sponsors and collaborators

The Cleveland Clinic

Lead sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator